Nonhomogeneous Gadolinium Retention in the Cerebral Cortex after Intravenous Administration of Gadolinium-based Contrast Agent in Rats and Humans.

Radiology

From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston Univ

Published: February 2020


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background Gadolinium retention after repeated gadolinium-based contrast agent (GBCA) exposure has been reported in subcortical gray matter. However, gadolinium retention in the cerebral cortex has not been systematically investigated. Purpose To determine whether and where gadolinium is retained in rat and human cerebral cortex. Materials and Methods The cerebral cortex in Sprague-Dawley rats treated with gadopentetate dimeglumine (three doses over 4 weeks; cumulative gadolinium dose, 7.2 mmol per kilogram of body weight; = 6) or saline ( = 6) was examined with antemortem MRI. Two human donors with repeated GBCA exposure (three and 15 doses; 1 and 5 months after exposure), including gadopentetate dimeglumine, and two GBCA-naive donors were also evaluated. Elemental brain maps (gadolinium, phosphorus, zinc, copper, iron) for rat and human brains were constructed by using laser ablation inductively coupled plasma mass spectrometry. Results Gadopentetate dimeglumine-treated rats showed region-, subregion-, and layer-specific gadolinium retention in the neocortex (anterior cingulate cortex: mean gadolinium concentration, 0.28 µg ∙ g ± 0.04 [standard error of the mean]) that was comparable ( > .05) to retention in the allocortex (mean gadolinium concentration, 0.33 µg ∙ g ± 0.04 in piriform cortex, 0.24 µg ∙ g ± 0.04 in dentate gyrus, 0.17 µg ∙ g ± 0.04 in hippocampus) and subcortical structures (0.47 µg ∙ g ± 0.10 in facial nucleus, 0.39 µg ∙ g ± 0.10 in choroid plexus, 0.29 µg ∙ g ± 0.05 in caudate-putamen, 0.26 µg ∙ g ± 0.05 in reticular nucleus of the thalamus, 0.24 µg ∙ g ± 0.04 in vestibular nucleus) and significantly greater than that in the cerebellum (0.17 µg ∙ g ± 0.03, = .01) and white matter tracts (anterior commissure: 0.05 µg ∙ g ± 0.01, = .002; corpus callosum: 0.05 µg ∙ g ± 0.02, = .001; cranial nerve: 0.02 µg ∙ g ± 0.01, = .004). Retained gadolinium colocalized with parenchymal iron. T1-weighted MRI signal intensification was not observed. Gadolinium retention was detected in the cerebral cortex, pia mater, and pia-ensheathed leptomeningeal vessels in two GBCA-exposed human brains but not in two GBCA-naive human brains. Conclusion Repeated gadopentetate dimeglumine exposure is associated with gadolinium retention in specific regions, subregions, and layers of cerebral cortex that are critical for higher cognition, affect, and behavior regulation, sensorimotor coordination, and executive function. © RSNA, 2019 See also the editorial by Kanal in this issue.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996690PMC
http://dx.doi.org/10.1148/radiol.2019190461DOI Listing

Publication Analysis

Top Keywords

µg ∙
52
gadolinium retention
24
cerebral cortex
24
∙ 004
20
µg
13
13
gadopentetate dimeglumine
12
human brains
12
gadolinium
11
retention cerebral
8

Similar Publications

Background: This systematic review aimed to evaluate whether specific single nucleotide polymorphisms (SNPs) in miRNAs are associated with recurrent implantation failure (RIF).

Methods: A comprehensive literature search was conducted across PubMed-MEDLINE, Web of Science, Scopus, and the Excerpta Medica DataBASE.

Results: The Newcastle-Ottawa Scale (NOS) yielded an intermediate to high quality, with one study rated with 6 stars, and the remaining four with 7 stars.

View Article and Find Full Text PDF

Potency is a critical quality attribute for vaccine development as well as clinical drug product (DP) lot release and stability testing. Animal studies have the potential to offer conclusive insights about the potency of vaccines by demonstrating technical relevance with respect to the hypothesized vaccine mode of action. However, animal studies are expensive, time-consuming, labor intensive, and, most importantly, involve the use of animals.

View Article and Find Full Text PDF

Background: Beginning in January 2025, all new active substances must undergo evaluation of relative clinical effectiveness through European Union (EU) joint clinical assessments (JCAs). In the absence of head-to-head data, indirect treatment comparisons (ITCs) become indispensable in meeting the numerous population, intervention, comparators and outcomes (PICO) criteria to support decision-making.

Objective: This study examined ITCs in European Network for Health Technology Assessment (EUnetHTA) relative effectiveness assessments (REAs) to obtain valuable insights into their potential implications for future JCAs.

View Article and Find Full Text PDF

Optic neuritis is an inflammatory demyelinating disease of the optic nerve that often occurs in multiple sclerosis (MS) patients. Sixty percent of patients develop some level of permanent visual loss due to retinal ganglion cell (RGC) damage following optic neuritis, with no known treatment to prevent this loss. Prior studies showed that MP201, a prodrug of 2,4-dinitrophenol (DNP) administered in the experimental autoimmune encephalitis (EAE) mouse model of MS attenuated optic neuritis with preserved vision, increased retinal ganglion cell (RGC) survival, decreased axon loss, and reduced demyelination.

View Article and Find Full Text PDF

Myocardial infarction (MI) is a multifactorial polygenic disease that develops as a result of a complex interaction of numerous genetic factors and the external environment. Accordingly, the contribution of each of them separately is usually not large and may significantly depend on the state of other accompanying factors. The purpose of the study was to search for informative predictors of MI risk based on polygenic analysis of polymorphic variants of (1) the antioxidant defense enzyme genes PON1 (rs662), PON2 (rs7493), CAT (rs1001179), MSRA (rs10098474) and GSTP1 (rs1695); (2) the apoptosis genes CASP8 (rs3834129), TP53 (rs1042522) and BCL2 (rs12454712); and (3) the inflammation genes CRP (rs1205), CX3CR1 (rs3732378), IL6 (rs1800795) and CCL2 (rs1024611).

View Article and Find Full Text PDF